Chronic migraine: risk factors, mechanisms and treatment

被引:416
作者
May, Arne [1 ]
Schulte, Laura H. [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Martinistr 52, D-20246 Hamburg, Germany
关键词
VAGUS NERVE-STIMULATION; MEDICATION-OVERUSE HEADACHE; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; IDIOPATHIC INTRACRANIAL HYPERTENSION; CORTICAL SPREADING DEPRESSION; BOTULINUM-TOXIN-A; DOUBLE-BLIND; EPISODIC MIGRAINE; PROPHYLACTIC TREATMENT;
D O I
10.1038/nrneurol.2016.93
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chronic migraine has a great detrimental influence on a patient's life, with a severe impact on socioeconomic functioning and quality of life. Chronic migraine affects 1-2% of the general population, and about 8% of patients with migraine; it usually develops from episodic migraine at an annual conversion rate of about 3%. The chronification is reversible: about 26% of patients with chronic migraine go into remission within 2 years of chronification. The most important modifiable risk factors for chronic migraine include overuse of acute migraine medication, ineffective acute treatment, obesity, depression and stressful life events. Moreover, age, female sex and low educational status increase the risk of chronic migraine. The pathophysiology of migraine chronification can be understood as a threshold problem: certain predisposing factors, combined with frequent headache pain, lower the threshold of migraine attacks, thereby increasing the risk of chronic migraine. Treatment options include oral medications, nerve blockade with local anaesthetics or corticoids, and neuromodulation. Well-defined diagnostic criteria are crucial for the identification of chronic migraine. The International Headache Society classification of chronic migraine was recently updated, and now allows co-diagnosis of chronic migraine and medication overuse headache. This Review provides an up-to-date overview of the classification of chronic migraine, basic mechanisms and risk factors of migraine chronification, and the currently established treatment options.
引用
收藏
页码:455 / 464
页数:10
相关论文
共 162 条
[1]   Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway [J].
Andreou, Anna P. ;
Goadsby, Peter J. .
CEPHALALGIA, 2011, 31 (13) :1343-1358
[2]   GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus [J].
Andreou, Anna P. ;
Shields, Kevin G. ;
Goadsby, Peter J. .
NEUROBIOLOGY OF DISEASE, 2010, 37 (02) :314-323
[3]   Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine [J].
Antal, Andrea ;
Kriener, Naomi ;
Lang, Nicolas ;
Boros, Klara ;
Paulus, Walter .
CEPHALALGIA, 2011, 31 (07) :820-828
[4]   Depression and risk of transformation of episodic to chronic migraine [J].
Ashina, Sait ;
Serrano, Daniel ;
Lipton, Richard B. ;
Maizels, Morris ;
Manack, Aubrey N. ;
Turkel, Catherine C. ;
Reed, Michael L. ;
Buse, Dawn C. .
JOURNAL OF HEADACHE AND PAIN, 2012, 13 (08) :615-624
[5]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[6]   OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program [J].
Aurora, Sheena K. ;
Winner, Paul ;
Freeman, Marshall C. ;
Spierings, Egilius L. ;
Heiring, Jessica O. ;
DeGryse, Ronald E. ;
VanDenburgh, Amanda M. ;
Nolan, Marissa E. ;
Turkel, Catherine C. .
HEADACHE, 2011, 51 (09) :1358-1373
[7]   Suppression of cortical spreading depression in migraine prophylaxis [J].
Ayata, C ;
Jin, HW ;
Kudo, C ;
Dalkara, T ;
Moskowitz, MA .
ANNALS OF NEUROLOGY, 2006, 59 (04) :652-661
[8]   Does chronic daily headache arise de novo in association with regular use of analgesics? [J].
Bahra, A ;
Walsh, M ;
Menon, S ;
Goadsby, PJ .
HEADACHE, 2003, 43 (03) :179-190
[9]   Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study [J].
Barbanti, Piero ;
Grazzi, Licia ;
Egeo, Gabriella ;
Padovan, Anna Maria ;
Liebler, Eric ;
Bussone, Gennaro .
JOURNAL OF HEADACHE AND PAIN, 2015, 16
[10]   Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas [J].
Becerra, L. ;
Bishop, J. ;
Barmettler, G. ;
Xie, Y. ;
Navratilova, E. ;
Porreca, F. ;
Borsook, D. .
JOURNAL OF NEUROPHYSIOLOGY, 2016, 115 (01) :208-217